Comparison of Glucovance to Insulin for Diabetes During Pregnancy
Primary Purpose
Gestational Diabetes, Type 2 Diabetes, Pregnancy
Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Insulin versus glucovance (glyburide/metformin)
Sponsored by
About this trial
This is an interventional treatment trial for Gestational Diabetes focused on measuring Diabetes, Pregnancy
Eligibility Criteria
Inclusion Criteria:Gestational diabetes by ACOG definition or Type 2 diabetes in pregnancy Hyperglycemia despite following ADA diet English or Spanish speaking - Exclusion Criteria:Already requiring Insulin Serum creatinine > 1.3 or creatinine clearance < 75ml/minute Liver disease -
Sites / Locations
- Regional Obstetrical ConsultantsRecruiting
Outcomes
Primary Outcome Measures
Maternal hemoglobin A1C at delivery
Maternal fructosamine at delivery
Maternal glucose at delivery
Secondary Outcome Measures
Mode of delivery
Infant birth weight
Infant initial glucose
Infant complications
Full Information
NCT ID
NCT00371306
First Posted
September 1, 2006
Last Updated
April 19, 2007
Sponsor
Regional Obstetrical Consultants
1. Study Identification
Unique Protocol Identification Number
NCT00371306
Brief Title
Comparison of Glucovance to Insulin for Diabetes During Pregnancy
Official Title
A Comparison of Glucovance (Glyburide and Metformin) to Insulin Therapy for the Treatment of Gestational Diabetes and Adult Onset Diabetes in Pregnancy
Study Type
Interventional
2. Study Status
Record Verification Date
April 2007
Overall Recruitment Status
Unknown status
Study Start Date
September 2002 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
September 2008 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Regional Obstetrical Consultants
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Pregnant women with gestational or Type 2 diabetes who require medication are placed in one of two groups: Insulin injections or Glucovance (oral administration). Blood glucose is checked 5 times per day, and medication adjusted by perinatologist according to glucose levels. The hypothesis is that patients will have similar or improved blood glucose control on an oral agent as compared to control on insulin.
Detailed Description
According to ACOG guidelines, patients between 24 and 28 weeks gestation will be screened with a 1 hour glucose tolerance test (GTT) by their obstetrician. Those with elevated glucose levels will undergo a 3 hour GTT. According to routine OB standards, if the blood glucose is elevated on 2 or more of 4 parameters during this test (> 95 fasting, > 180 at 1 hour, > 155 at 2 hours, >140 at 3 hours), the patient will begin receiving dietary therapy using ADA guidelines. If blood glucose levels remain 20% above a fasting of 90 & post parandial of 120 with diet alone during a period of 1-3 weeks after diagnosis, the patient will be invited to participate in this study. Type 2 diabetics who have been diagnosed prior to pregnancy will also be included. These patients may enroll in the study prior to 24 weeks gestation, entering at the time of referral. Patients who give consent for participation will be randomly assigned to either insulin therapy (the usual standard of care), or to oral Glucovance therapy (the experimental group). Glucovance will be started at 1.25mg/250mg BID. NPH & regular Insulin will be started on a 1unit/kg basis BID. Both groups will receive care according to the current standard for gestational diabetics and pregnant Type 2 diabetics. The perinatologist and diabetes educator will evaluate the blood glucose record and assess the patient's adherence to the ADA diet weekly and will determine when the insulin or Glucovance needs to be increased. If the patients in the Glucovance group continue to be poorly controlled with 4 tablets/day (5mg/500mg), the therapy will be continued and insulin will be added to the management. Statistical analysis will compare the two groups for myriad factors including vaginal versus operative deliveries, hemoglobin A1C, fructosamine, and glucose at delivery, infant birth weight, infant complications, initial infant blood glucose.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gestational Diabetes, Type 2 Diabetes, Pregnancy
Keywords
Diabetes, Pregnancy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Single
Allocation
Randomized
Enrollment
200 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Insulin versus glucovance (glyburide/metformin)
Primary Outcome Measure Information:
Title
Maternal hemoglobin A1C at delivery
Title
Maternal fructosamine at delivery
Title
Maternal glucose at delivery
Secondary Outcome Measure Information:
Title
Mode of delivery
Title
Infant birth weight
Title
Infant initial glucose
Title
Infant complications
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:Gestational diabetes by ACOG definition or Type 2 diabetes in pregnancy Hyperglycemia despite following ADA diet English or Spanish speaking -
Exclusion Criteria:Already requiring Insulin Serum creatinine > 1.3 or creatinine clearance < 75ml/minute Liver disease
-
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lorrie A Mason, MSN
Phone
423 664-4460
Email
lorrie@rocob.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joseph H Kipikasa, MD
Organizational Affiliation
Regional Obstetrical Consultants; UT Chattanooga OB-GYN Department
Official's Role
Principal Investigator
Facility Information:
Facility Name
Regional Obstetrical Consultants
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37403
Country
United States
Individual Site Status
Recruiting
12. IPD Sharing Statement
Learn more about this trial
Comparison of Glucovance to Insulin for Diabetes During Pregnancy
We'll reach out to this number within 24 hrs